This article was originally published in The Gray Sheet
Firm orchestrates a $3.5 mil. round of financing through the issuance of 5% Series C convertible preferred stock. Proceeds are tabbed to support expanded marketing initiatives aimed at increasing awareness among physicians, patients and insurers of the firm's EECP (enhanced external counterpulsation) non-invasive technology for treatment of angina pectoris in patients with coronary disease. Specific programs will include patient outreach initiatives and those aimed at demonstrating to HMOs the economic benefits of the device
You may also be interested in...
Suspension of heartburn remedy ranitidine looming in the EU as the European Medicines Agency stands by its original decision.
Illumina announced on 21 September it will buy back Grail, which is planning to commercialize its multi-cancer early detection blood test Galleri in 2021. See what Illumina’s CEO Francis deSouza said about it here.
Yes, Gottlieb’s in there twice; things get complicated when an agency starts to lose credibility.